Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies.

ABSTRACT:

Purpose

Cardiac dysfunction, particularly QT interval prolongation, has been observed with tyrosine kinase inhibitors approved to treat chronic myeloid leukemia. This study examines the effects of ponatinib on cardiac repolarization in patients with refractory hematological malignancies enrolled in a phase 1 trial.

Methods

Electrocardiograms (ECGs) were collected at 3 dose levels (30, 45, and 60 mg) at 6 time points. Electrocardiographic parameters, including QTc interval, were measured, and 11 morphological analyses were conducted. Central tendency analyses of ECG parameters were performed using time-point and time-averaged approaches. All patients with at least 2 baseline ECGs and 1 on-treatment ECG were included in the analyses. Patients with paired ECGs and plasma sample

SUBMITTER: Sonnichsen D 

PROVIDER: S-EPMC3668123 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature